166 related articles for article (PubMed ID: 37341812)
1. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.
Brito MJ; Sequeira P; Quintas A; Silva I; Silva F; Martins C; Félix A
Virchows Arch; 2024 Mar; 484(3):507-516. PubMed ID: 37341812
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV.
Lovane L; Tulsidás S; Carrilho C; Karlsson C
Sci Rep; 2024 Jun; 14(1):12974. PubMed ID: 38839923
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 expression in carcinoma of unknown primary.
Kim HM; Koo JS
BMC Cancer; 2024 Jun; 24(1):689. PubMed ID: 38844907
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.
Chinn Z; Stoler MH; Mills AM
Histopathology; 2019 Jan; 74(2):256-268. PubMed ID: 30067880
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
[TBL] [Abstract][Full Text] [Related]
6. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
7. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
8. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
10. Programmed death ligand 1 (PD-L1) expression in parathyroid tumors.
Pan B; Wang A; Pang J; Zhang Y; Cui M; Sun J; Liang Z
Endocr Connect; 2019 Jul; 8(7):887-897. PubMed ID: 31252398
[TBL] [Abstract][Full Text] [Related]
11. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions.
Yoshida T; Sano T; Kanuma T; Owada N; Sakurai S; Fukuda T; Nakajima T
Cancer; 2008 Apr; 114(2):83-8. PubMed ID: 18300235
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
[TBL] [Abstract][Full Text] [Related]
13. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
15. Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands- A nationwide evaluation study.
Hempenius MA; Koomen BM; Deckers IAG; Oosting SF; Willems SM; van der Vegt B
Histopathology; 2024 Jul; 85(1):133-142. PubMed ID: 38606992
[TBL] [Abstract][Full Text] [Related]
16. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Tanigawa M; Naito Y; Akiba J; Kawahara A; Okabe Y; Ishida Y; Ishikawa H; Hisaka T; Fujita F; Yasunaga M; Shigaki T; Sudo T; Mihara Y; Nakayama M; Kondo R; Kusano H; Shimamatsu K; Okuda K; Akagi Y; Yano H
Pathol Res Pract; 2018 Dec; 214(12):2069-2074. PubMed ID: 30477643
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives.
Kim SY; Kim TE; Park CK; Yoon HK; Sa YJ; Kim HR; Woo IS; Kim TJ
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804910
[TBL] [Abstract][Full Text] [Related]
19. Anal Squamous Intraepithelial Lesions (SILs) in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men: Incidence and Risk Factors of SIL and of Progression and Clearance of Low-Grade SILs.
Jongen VW; Richel O; Marra E; Siegenbeek van Heukelom ML; van Eeden A; de Vries HJC; Cairo I; Prins JM; Schim van der Loeff MF
J Infect Dis; 2020 Jun; 222(1):62-73. PubMed ID: 31755920
[TBL] [Abstract][Full Text] [Related]
20. Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in Africa. Dyscer-CI Group.
La Ruche G; Ramon R; Mensah-Ado I; Bergeron C; Diomandé M; Sylla-Koko F; Ehouman A; Touré-Coulibaly K; Welffens-Ekra C; Dabis F
Cancer; 1998 Jun; 82(12):2401-8. PubMed ID: 9635533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
